Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varlitinib plus capecitabine in advanced or metastatic biliary tract cancer
NCT03129074Phase 2Withdrawn
- Sponsor
- ASLAN Pharmaceuticals
- Start
- May 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of varlitinib in biliary tract cancer (BTC), sponsored by ASLAN Pharmaceuticals. Planned start May 2018; status: withdrawn.
02
Drugs
varlitinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03129074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03129074.